Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Saved in:
| Title: | Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. |
|---|---|
| Authors: | Horn, Leora1 leora.horn@vanderbilt.edu, Gettinger, Scott2 scott.gettinger@yale.edu, Camidge, D. Ross3 ross.camidge@ucdenver.edu, Smit, Egbert F.4 EF.Smit@vumc.nl, Janjigian, Yelena Y.5 janjigiy@mskcc.org, Miller, Vincent A.6 vmiller@foundationmedicine.com, Pao, William1 william.pao@vanderbilt.edu, Freiwald, Matthias7 matthias.freiwald@boehringer-ingelheim.com, Fan, Jean8 jean.fan@boehringer-ingelheim.com, Wang, Bushi8 bushi.wang@boehringer-ingelheim.com, Chand, Vikram K.8 vikramkchand@gmail.com, Groen, Harry J.M.9 h.j.m.groen@umcg.nl |
| Source: | Lung Cancer (01695002). Nov2017, Vol. 113, p51-58. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
